Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Orchestra BioMed Holdings, Inc. - Ordinary Shares (NQ:OBIO)

4.410 -0.040 (-0.90%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Orchestra BioMed Holdings, Inc. - Ordinary Shares

< Previous 1 2 3 Next >
News headline image
Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed to Participate in Upcoming Investor Conferences
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed to Present at the Jefferies Global Healthcare Conference
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed to Present at Upcoming Investor Conferences
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Strengthens Senior Leadership Team
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.